Literature DB >> 12435711

Phenotypic and genotypic analysis of biologically cloned human immunodeficiency virus type 1 isolates from patients treated with zidovudine and lamivudine.

Thomas C Stoeckli1, Samantha MaWhinney, Jonathan Uy, Chengying Duan, Jing Lu, David Shugarts, Daniel R Kuritzkes.   

Abstract

Mutations at reverse transcriptase codons 44, 118, 207, and 208 were significantly correlated with reduced zidovudine susceptibility in biologically cloned human immunodeficiency virus type 1 (HIV-1) isolates. Sequences from the Stanford HIV RT and Protease Sequence Database showed that these mutations were more common in HIV-1 isolates from patients treated with zidovudine and lamivudine than in patients not treated with these drugs.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12435711      PMCID： PMC132743          DOI： 10.1128/AAC.46.12.4000-4003.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  18 in total

1.  Prevalence and conditions of selection of E44D/A and V118I human immunodeficiency virus type 1 reverse transcriptase mutations in clinical practice.

Authors:  C Delaugerre; M Mouroux; A Yvon-Groussin; A Simon; F Angleraud; J M Huraux; H Agut; C Katlama; V Calvez
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

2.  Broad nucleoside-analogue resistance implications for human immunodeficiency virus type 1 reverse-transcriptase mutations at codons 44 and 118.

Authors:  Laura Romano; Giulietta Venturi; Stuart Bloor; Richard Harrigan; Brendan A Larder; Jennifer C Major; Maurizio Zazzi
Journal:  J Infect Dis       Date:  2002-03-11       Impact factor: 5.226

3.  A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy.

Authors:  Calvin J Cohen; Susan Hunt; Michael Sension; Charles Farthing; Marcus Conant; Susan Jacobson; Jeffrey Nadler; Werner Verbiest; Kurt Hertogs; Michael Ames; Alex R Rinehart; Neil M Graham
Journal:  AIDS       Date:  2002-03-08       Impact factor: 4.177

4.  Multiple sites in HIV-1 reverse transcriptase associated with virological response to combination therapy.

Authors:  H M Precious; H F Günthard; J K Wong; R T D'Aquila; V A Johnson; D R Kuritzkes; D D Richman; A J Leigh Brown
Journal:  AIDS       Date:  2000-01-07       Impact factor: 4.177

5.  A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V.

Authors:  K Hertogs; S Bloor; V De Vroey; C van Den Eynde; P Dehertogh; A van Cauwenberge; M Stürmer; T Alcorn; S Wegner; M van Houtte; V Miller; B A Larder
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

6.  The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis.

Authors:  M Götte; D Arion; M A Parniak; M A Wainberg
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

7.  Standardization of sensitive human immunodeficiency virus coculture procedures and establishment of a multicenter quality assurance program for the AIDS Clinical Trials Group. The NIH/NIAID/DAIDS/ACTG Virology Laboratories.

Authors:  F B Hollinger; J W Bremer; L E Myers; J W Gold; L McQuay
Journal:  J Clin Microbiol       Date:  1992-07       Impact factor: 5.948

8.  Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.

Authors:  M Tisdale; S D Kemp; N R Parry; B A Larder
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-15       Impact factor: 11.205

9.  Phenotypic mechanism of HIV-1 resistance to 3'-azido-3'-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase.

Authors:  D Arion; N Kaushik; S McCormick; G Borkow; M A Parniak
Journal:  Biochemistry       Date:  1998-11-10       Impact factor: 3.162

10.  Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working Group.

Authors:  A J Japour; D L Mayers; V A Johnson; D R Kuritzkes; L A Beckett; J M Arduino; J Lane; R J Black; P S Reichelderfer; R T D'Aquila
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191
View more
  6 in total

1.  Analysis of selection pressure and mutational pattern of HIV type 1 reverse transcriptase region among treated and nontreated patients.

Authors:  Uma Shanmugasundaram; Suniti Solomon; Vidya Madhavan; Murugavel G Kailapuri; Kumarasamy Nagalingeswaran; Sunil Suhas Solomon; Kenneth H Mayer; Balakrishnan Pachamuthu
Journal:  AIDS Res Hum Retroviruses       Date:  2010-09-19       Impact factor: 2.205

Review 2.  HIV-1 drug resistance mutations: an updated framework for the second decade of HAART.

Authors:  Robert W Shafer; Jonathan M Schapiro
Journal:  AIDS Rev       Date:  2008 Apr-Jun       Impact factor: 2.500

3.  Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors.

Authors:  Valentina Svicher; Tobias Sing; Maria Mercedes Santoro; Federica Forbici; Fátima Rodríguez-Barrios; Ada Bertoli; Niko Beerenwinkel; Maria Concetta Bellocchi; Federigo Gago; Antonella d'Arminio Monforte; Andrea Antinori; Thomas Lengauer; Francesca Ceccherini-Silberstein; Carlo Federico Perno
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

4.  N348I in reverse transcriptase provides a genetic pathway for HIV-1 to select thymidine analogue mutations and mutations antagonistic to thymidine analogue mutations.

Authors:  Jessica Radzio; Soo-Huey Yap; Gilda Tachedjian; Nicolas Sluis-Cremer
Journal:  AIDS       Date:  2010-03-13       Impact factor: 4.177

5.  Mechanisms by which the G333D mutation in human immunodeficiency virus type 1 Reverse transcriptase facilitates dual resistance to zidovudine and lamivudine.

Authors:  Shannon Zelina; Chih-Wei Sheen; Jessica Radzio; John W Mellors; Nicolas Sluis-Cremer
Journal:  Antimicrob Agents Chemother       Date:  2007-10-29       Impact factor: 5.191

6.  A counting renaissance: combining stochastic mapping and empirical Bayes to quickly detect amino acid sites under positive selection.

Authors:  Philippe Lemey; Vladimir N Minin; Filip Bielejec; Sergei L Kosakovsky Pond; Marc A Suchard
Journal:  Bioinformatics       Date:  2012-10-12       Impact factor: 6.937
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.